11.07.2015 Views

Novel genetic and epigenetic alterations in ... - Ous-research.no

Novel genetic and epigenetic alterations in ... - Ous-research.no

Novel genetic and epigenetic alterations in ... - Ous-research.no

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Introductionthere seems to be a fidelity threshold for homopolymer tracts, where those longer than 7base pairs are considered much less stable than those of seven or fewer units[80].With well over a thous<strong>and</strong> genes conta<strong>in</strong><strong>in</strong>g eight or more mo<strong>no</strong>nucleotide repeats <strong>in</strong> thege<strong>no</strong>me[90] it is obvious that mutations <strong>in</strong> these genes will accumulate at a much higher rateamong MSI tumors compared to tumors with a functional MMR-system. MSI is thereforeoften referred to as the mutator phe<strong>no</strong>type[91].CpG isl<strong>and</strong> methylator phe<strong>no</strong>type – CIMPWhile CIN tumors have a defect <strong>in</strong> the chromosomal segregation <strong>and</strong> MSI tumors have adefective MMR-system, the CIMP-tumors have a methylation mach<strong>in</strong>ery that has gone awry,caus<strong>in</strong>g epi<strong>genetic</strong> <strong>in</strong>stability[92]. Tumors with CIMP are therefore associated with promoterhypermethylation of a large number of genes. It has previously been shown that 38% ofCRC display neither CIN <strong>no</strong>r MSI, <strong>and</strong> it has been speculated whether this group hasepi<strong>genetic</strong> events as the malignant driv<strong>in</strong>g force[93]. The CIMP phe<strong>no</strong>type overlaps <strong>in</strong> alarge degree with MSI, result<strong>in</strong>g <strong>in</strong> many of the same cl<strong>in</strong>ical associations, such as proximallocation <strong>and</strong> female gender of old age[92]. Overall, CIMP is associated with a poor prog<strong>no</strong>siscompared to CIMP-negative tumors[94;95]. In addition, it has been shown to be an<strong>in</strong>dependent (from MSI <strong>and</strong> TP53 mut ) positive predictor of survival benefit from 5-FUtreatment[96]. On the <strong>genetic</strong> level, CIMP is strongly associated with the V600E mutation <strong>in</strong>BRAF, KRAS mut , <strong>and</strong> TP53 wt [97;98], which has led to the suggestion of two CIMP-groups;CIMP1 which is associated with extensive hypermethylation, V600E mutation <strong>in</strong> BRAF <strong>and</strong>MSI; CIMP2, an <strong>in</strong>termediate group with less frequent hypermethylation than CIMP1 as wellas KRAS mutation; <strong>and</strong> the CIMP negative group which conta<strong>in</strong>s very scarce methylation,microsatellite stable <strong>and</strong> wild-type TP53 tumors[98](Figure 11). CIMP is <strong>in</strong>versely associatedwith mutations <strong>in</strong> APC, the hallmark of early events <strong>in</strong> ade<strong>no</strong>mas[99], thus support<strong>in</strong>g thehypothesis that CIMP <strong>and</strong> MSI tumors orig<strong>in</strong>ate from the sessile serrated polyps <strong>and</strong> <strong>no</strong>tade<strong>no</strong>mas[100]. CIMP is <strong>no</strong>t exclusive for CRC. It has also been shown <strong>in</strong> gastric-, lung-,liver- <strong>and</strong> ovarian cancer as well as leukemia[95].30

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!